✦ LIBER ✦

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

✍ Scribed by Dimopoulos, M A; Kastritis, E; Christoulas, D; Migkou, M; Gavriatopoulou, M; Gkotzamanidou, M; Iakovaki, M; Matsouka, C; Mparmparoussi, D; Roussou, M

Book ID: 109887217
Publisher: Nature Publishing Group
Year: 2010
Tongue: English
Weight: 473 KB
Volume: 24
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2010.175

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Impact of prior therapies on the relativ

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma

✍ Dan T. Vogl; Edward A. Stadtmauer; Paul G. Richardson; Pieter Sonneveld; Michael 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB

The efficacy and safety of lenalidomide

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

✍ Meletios Dimopoulos; Adrian Alegre; Edward A. Stadtmauer; Hartmut Goldschmidt; J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 1 views

Dickkopf-1 and sclerostin in different p

Dickkopf-1 and sclerostin in different phases of multiple myeloma; The effect of lenalidomide and dexamethasone treatment with or without bortezomib

✍ E. Terpos; D. Christoulas; M. Gkotzamanidou; C. Bratengeier; M. Gavriatopoulou; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 67 KB

Impact of high-risk cytogenetics and pri

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

✍ Avet-Loiseau, H; Soulier, J; Fermand, J-P; Yakoub-Agha, I; Attal, M; Hulin, C; G 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 313 KB

A comparison of bortezomib, cyclophospha

A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma

✍ Ahn, Jae-Sook; Yang, Deok-Hwan; Jung, Sung-Hoon; Park, Hyung Chul; Moon, Joon Ho 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 224 KB

High response rate to bortezomib with or

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program

✍ Joseph R. Mikhael; Andrew R. Belch; H. Miles Prince; Maria Nambo Lucio; Angelo M 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 272 KB